Skip to main content

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma

Pathology & Oncology Research volume 20, pages 445–451 (2014)Cite this article

Abstract

Mutation of epidermal growth factor receptor (EGFR) gene has been reported to be present in lung adenocarcinoma (LAC). In this study, we extensively investigated the impact of patients’ biological characteristics on EGFR mutation and the impact of EGFR mutation subtypes on targeted therapy of advanced LAC. We examined EGFR exons18to21status in169 LAC patients by direct sequencing to study the impact of patients’ biological characteristics on the EGFR mutational spectrum. And then, 59 patients with advanced LAC harboring EGFR exon 19 deletions(del 19) or exon 21 point mutation(L858R) mutations received first-line treatment of gefitinib or erlotinib, the efficacy of treatment, and the progression-free survival (PFS) of these patients were recorded. The frequency of the EGFR mutation and its subtypes and the variables associated with the EGFR mutation after removing the confound factors were investigated by the logistic analysis using all samples (n = 169). The EGFR mutation was significantly associated with well-differentiated tumor and excessive household cooking fumes(P < 0.05). The deletions in exon 19 were more frequently associated with well-differentiated tumor (P < 0.05). The overall frequency of the EGFR mutation was 49 %. Then the impact of EGFR mutation subtypes on targeted therapy were investigated by the retrospective analysis on 59 advanced LAC patients with del 19 or L858R mutations and treated first-line with erlotinib or gefitinib. The deletions in exon 19 got longer PFS (P < 0.05). But there were no differences in PFS between erlotinib therapy and gefitinib therapy. EGFR mutations were more frequently in high tumor differentiation and excessive household cooking fumes LAC. The del 19 mutation rate is relatively high with a high differentiation degree in advanced lung adenocarcinoma. The deletions in exon 19 may benefit more from first-line targeted therapy of advanced LAC compared with exon 21 point mutation L858R. There was no significant difference between the efficacy of gefitinib and erlotinib treatments associated with EGFR mutation and its subtypes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

Abbreviations

LAC:

Lung adenocarcinoma

EGFR:

Epidermal growth factor receptor

del 19:

Exon 19 deletions

L858R:

Exon 21 point mutation

PFS:

Progression-free survival

References

  1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29

    PubMed  Article  Google Scholar 

  2. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380

    PubMed  Article  CAS  Google Scholar 

  3. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957

    PubMed  Article  CAS  Google Scholar 

  4. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128

    PubMed  Article  CAS  Google Scholar 

  5. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139

    PubMed  Article  CAS  Google Scholar 

  6. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500

    PubMed  Article  CAS  Google Scholar 

  7. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957

    PubMed  Article  CAS  Google Scholar 

  8. Yang CH, Yu CJ, Shih JY et al (2008) Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26(16):2745–2753

    PubMed  Article  CAS  Google Scholar 

  9. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967

    PubMed  Article  CAS  Google Scholar 

  10. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527–1537

    PubMed  Article  CAS  Google Scholar 

  11. Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132

    PubMed  Article  CAS  Google Scholar 

  12. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101(36):13306–13311

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  13. Taron M, Ichinose Y, Rosell R et al (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11(16):5878–5885

    PubMed  Article  CAS  Google Scholar 

  14. Uramoto H, Sugio K, Oyama T et al (2006) Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51(1):71–77

    PubMed  Article  Google Scholar 

  15. Li M, Yin Z, Guan P et al (2008) XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer 62(2):145–151

    PubMed  Article  Google Scholar 

  16. Ko YC, Cheng LS, Lee CH et al (2000) Chinese food cooking and lung cancer in women nonsmokers. Am J Epidemiol 151(2):140–147

    PubMed  Article  CAS  Google Scholar 

  17. Metayer C, Wang Z, Kleinerman RA et al (2002) Cooking oil fumes and risk of lung cancer in women in rural Gansu. China Lung Cancer 35(2):111–117

    Article  Google Scholar 

  18. Lin Y, Cai L (2012) Environmental and dietary factors and lung cancer risk among Chinese women: a case–control study in Southeast China. Nutr Cancer 64(4):508–514

    PubMed  Article  Google Scholar 

  19. Yang HH, Chien SM, Lee HL et al (2007) Emission of trans,trans-2,4-decadienal from restaurant exhausts to the atmosphere. Atmos Environ, 41: 5327–5333

    Google Scholar 

  20. Chang LW, Lo WS, Lin P (2005) Trans, trans-2,4-decadienal, a product found in cooking oil fumes, induces cell proliferation and cytokine production due to reactive oxygen species in human bronchial epithelial cells. Toxicol Sci 87(2):337–343

    PubMed  Article  CAS  Google Scholar 

  21. Meng-hong S, Fei Y, Lei S (2011) Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types. Chinese J Pathol 40(10):655–659

    Google Scholar 

  22. Miao-Jin F, Hai-Gang L, Zhi-Qiang L et al (2011) Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer. Chinese J Pathol 40(10):679–682

    Google Scholar 

  23. Tomizawa Y, Iijima H, Sunaga N et al (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11(19 Pt 1):6816–6822

    PubMed  Article  CAS  Google Scholar 

  24. Tam IY, Chung LP, Suen WS et al (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12(5):1647–1653

    PubMed  Article  CAS  Google Scholar 

  25. Rosell R, Moran T, Queralt C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967

    PubMed  Article  CAS  Google Scholar 

  26. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118(2):257–262

    PubMed  Article  CAS  Google Scholar 

  27. Kim ST, Lee J, Kim JH et al (2010) Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer 116(12):3025–3033

    PubMed  Article  CAS  Google Scholar 

  28. Kim ST, Uhm JE, Lee J et al (2012) Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 75(1):82–88

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Respiratory, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China

    Rong-li Lu, Cheng-Ping Hu, Hua-ping Yang, Yuan-yuan Li & Qi-hua Gu

  2. Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China

    Lielin Wu

Authors
  1. Rong-li Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cheng-Ping Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua-ping Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuan-yuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qi-hua Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lielin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cheng-Ping Hu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lu, Rl., Hu, CP., Yang, Hp. et al. Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma. Pathol. Oncol. Res. 20, 445–451 (2014). https://doi.org/10.1007/s12253-013-9715-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9715-0

Keywords

  • Lung adenocarcinoma(LAC)
  • Epidermal growth factor receptor (EGFR)
  • Erlotinib
  • Gefitinib
  • Exon 19 deletions(del 19)
  • Exon 21 point mutation(L858R)